Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
In Re: Nexium (Esomeprazole) Antitrust Litigation
Case Number:
1:12-md-02409
Court:
Nature of Suit:
Multi Party Litigation:
Class Action, Multi-district Litigation
Judge:
Firms
- Andrews DeValerio
- Baker & Hostetler
- Berger Montague
- Berman Tabacco
- Buchanan Ingersoll
- Carella Byrne
- Cohen Milstein
- Cohn Lifland
- Conn Kavanaugh
- Covington & Burling
- Douglas & London
- Dugan Law Firm
- Faruqi & Faruqi
- Fisher & Phillips
- Foley & Lardner
- FrancoLaw PLLC
- Garwin Gerstein
- Girard Sharp
- Glancy Prongay
- Goldman Scarlato
- Hach Rose Schirripa
- Hagens Berman
- Hamilton Brook
- Hangley Aronchick
- Heim Payne
- Hilliard & Shadowen
- Jones Day
- Kenny Nachwalter
- Kirkland & Ellis
- Lowey Dannenberg
- Marcus & Shapira
- McCarter & English
- Miller Shah LLP
- Mintz Levin
- Morrison Foerster
- Nussbaum Law Group
- Radice Law Firm
- Schnader Harrison
- Shapiro Haber
- Shapiro & Teitelbaum
- Smith Segura
- Sperling & Slater
- Taus Cebulash
- Venable LLP
- Wexler Boley
- Wilentz Goldman
- Williams & Connolly
- Windels Marx
Companies
- AstraZeneca PLC
- Cardinal Health Inc.
- Careplus Health Plans Inc.
- CVS Health Corp.
- Dr. Reddy's Laboratories Ltd.
- Express Scripts Holding Co.
- Fraternal Order of Police
- Giant Eagle Inc.
- H‑E‑B LP
- Humana Inc.
- McKesson Corp.
- Ranbaxy
- Rite Aid Corp.
- Rochester Drug Cooperative Inc.
- Safeway Inc.
- Supervalu Inc.
- Teva Pharmaceutical Industries Ltd.
- The Kroger Co.
Sectors & Industries:
-
October 05, 2015
Nexium Buyers Get $8M Fees In Pay-For-Delay Settlement
A Massachusetts federal judge on Monday divvied out more than $8 million in expenses for a settlement reached between Nexium buyers and Teva Pharmaceutical Industries Ltd., but agreed to hold off on approving fees for AstraZeneca PLC and Ranbaxy Inc. following their win in a multidistrict litigation pay-for-delay trial brought by the same buyers.
-
September 29, 2015
Nexium Buyers Fight Drugmakers' Bid For Costs After Loss
Nexium buyers who lost at trial in the pay-for-delay multidistrict litigation against AstraZeneca PLC and Ranbaxy Inc. have asked a federal court not to award the drugmakers more than $423,000 in costs, saying it's an issue that would better be decided after appeal.
-
August 31, 2015
Nexium Pay-For-Delay Plaintiffs To Appeal Loss To 1st Circ.
The plaintiffs in the Nexium pay-for-delay multidistrict litigation against AstraZeneca PLC and generic-drug maker Ranbaxy Inc. on Friday appealed to the First Circuit a Massachusetts federal judge's refusal in July to grant them a new trial.
-
July 30, 2015
No New Trial For Drug Buyers In Nexium Pay-For-Delay Suit
A Massachusetts federal judge refused Thursday to let Nexium buyers get a second crack at their pay-for-delay suit against AstraZeneca PLC and Ranbaxy Inc., saying the plaintiffs' claim for how new evidence would let them prove their case at trial was "at least a couple of bridges too far."
-
June 30, 2015
Nexium Buyers Say 3rd Circ.'s Lamictal Ruling Backs New Trial
Plaintiffs in the Nexium pay-for-delay antitrust class action urged a Massachusetts federal court to grant them a new trial Monday because of the Third Circuit's recent Lamictal ruling that reverse payments do not need to include cash.
-
June 12, 2015
Teva Gets Nod For $24M Nexium Pay-For-Delay Settlement
A Massachusetts federal judge on Friday gave tentative approval to a $24 million settlement between Teva Pharmaceutical Industries Ltd. and class action plaintiffs in a pay-for-delay case over generic versions of AstraZeneca PLC's heartburn drug Nexium.
-
June 04, 2015
Nexium Buyers Say Namenda Ruling Supports Injunction Bid
Nexium purchasers told a Massachusetts federal court Thursday that the Second Circuit's recent ruling upholding an injunction requiring Actavis PLC to keep an Alzheimer's drug on the market supported their own bid for an injunction in pay-for-delay litigation against Ranbaxy Inc. and AstraZeneca PLC.
-
April 03, 2015
Class Says FDA Ruling Backs Nexium Pay-For-Delay Retrial
On the heels of losing a pay-for-delay trial against Ranbaxy Pharmaceuticals Inc. and AstraZeneca PLC over generic Nexium, class plaintiffs contended Thursday that a recent U.S. Food and Drug Administration decision and other developments back their retrial request.
-
April 02, 2015
Teva Strikes $24M Deal To Exit Nexium Pay-For-Delay Suit
Class action plaintiffs in a pay-for-delay case over generic versions of AstraZeneca PLC's heartburn drug Nexium disclosed on Thursday a $24 million settlement freeing Teva Pharmaceutical Industries Ltd. from the case, according to filings in Massachusetts federal court.
-
March 31, 2015
Ranbaxy, AstraZeneca Say Plaintiffs Lack Basis For New Trial
Ranbaxy Inc. and AstraZeneca PLC urged a Massachusetts federal court Monday to deny a bid by plaintiffs who lost a recent pay-for-delay class action trial over the heartburn drug Nexium to file a supplemental submission, saying it provided no basis for a new trial.